Blood Substitutes

Practical Transfusion Medicine

Volumn , Issue , 2013, Pages 399-409

  Roberts, David J ^a   Prowse, Chris V ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood substitutes; Embryonic stem cells; Haemoglobin based blood substitutes; Induced pluripotent stem cells; Nitric oxide; Perfluorocarbons; Platelet substitutes

Indexed keywords

EID: 84886577524     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118520093.ch36     Document Type: Chapter

References (26)

1. Shander A, Javidroozi M, Ozawa S&Hare GM. What is really dangerous: anaemia or transfusion? Br J Anaesth 2011; 107 (Suppl. 1): i41-59.
2. Jacobs T and Fischer J. When a long shot is worth a shot. Nature Biotechnol 2005; 23: 805.
3. Auker CR & McCarron RM. US Navy experience with research on, and development of, hemoglobin-based oxygen carriers. J Trauma 2011; 70 (5 Suppl.): S40-S41.
4. Natanson C, Kern SJ, Lurie P, Banks SM & Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. J Am Med Assoc 2008; 299: 2304-2312.
5. Dhillon S. Fibrin sealant (evicel® [quixil®/crossealTM]): a review of its use as supportive treatment for haemostasis in surgery. Drugs 2011; 71: 1893-1915.
6. Morrison JJ, Dubose JJ, Rasmussen TE & Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012; 147: 113-119.
7. Safo MK, Ahmed MH, Ghatge MS & Boyiri T. Hemoglobin-ligand binding: understanding Hb function and allostery on atomic level. Biochim Biophys Acta 2011; 1814: 797-809.
8. CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR&Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
9. Estep T, Bucci E, Farmer M, Greenburg G, Harrington J, Kim HW, Klein H, Mitchell P, Nemo G, Olsen K, Palmer A, Valeri CR & Winslow R. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop 2006. Transfusion 2008; 48: 776-782.
10. Jaspen B. FDA shoots down Northfield Labs blood substitute. Chicago Tribune 2009, April; 36.
11. Harris DR & Palmer AF. Modern cross-linking strategies for synthesizing acellular hemoglobin-based oxygen carriers. Biotechnol Prog 2008; 24: 1215-1225.
12. Lui FE & Kluger R. Enhancing nitrite reductase activity of modified hemoglobin: bis-tetramers and their PEGylated derivatives. Biochemistry 2009; 48: 11912-11919.
13. Fergusson DA & McIntyre L. The future of clinical trials evaluating blood substitutes. J Am Med Assoc 2008; 299: 2324-2326.
14. Carson JL, Carless PA&Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012; 4: CD002042.
15. Kluger R. Red cell substitutes from hemoglobin-do we start all over again? Curr Opin Chem Biol 2010; 14: 538-543.
16. Migliaccio AR, Whitsett C & Migliaccio G. Erythroid cells in vitro: from developmental biology to blood transfusion products. Curr Opin Hematol 2009; 16: 259-268.
17. Giarratana MC, Rouard H, Dumont A, Kiger L, Safeukui I, Le Pennec PY, François S, Trugnan G, Peyrard T, Marie T, Jolly S, Hebert N, Mazurier C, Mario N, Harmand L, Lapillonne H, Devaux JY & Douay L. Proof of principle for transfusion of in vitro-generated red blood cells. Blood 2011; 118: 5071-5079.
18. Okita K & Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Phil Trans R Soc Lond B Biol Sci 2011; 366: 2198-2207.
19. Lane TA. Perflurochemical-based artifical oxygen carrying red cell substitutes. Transfus Sci 1995; 16: 19-31.
20. Chao FC, Kim BK, HouraniehAMet al. Infusible platelet membrane (IPM) is a potential substitute for platelets in transfusion: correction of prolonged bleeding time in thrombocytopenic rabbits. Thromb Haemost 1993; 69: 750.
21. Baudin-Creuza V, Chauvierre C, Domingues E, Kiger L, Leclerc L, Vasseur C, Celier C & Marden MC. Octamers and nanoparticles as hemoglobin based blood substitutes. Biochim Biophys Acta Prot Proteom 2008; 1784: 1448-1453.
22. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 2003; 1: 1637-1641.
23. Blood substitute. Wikipedia. http://en.wikipedia.org/wiki/Blood_substitute. Accessed 10 June 2012.
24. Estep T, Bucci E, Farmer M, Greenburg G, Harrington J, Kim HW, Klein H, Mitchell P, Nemo G, Olsen K et al. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008; 48: 776-782.
25. Gladwin MT, Grubina R & Doyle MP. The new chemical biology of nitrite reactions with hemoglobin: Rstate catalysis, oxidative denitrosylation, and nitrite reductase/anhydrase. Acc Chem Res 2009; 42: 157-167.
26. Ker K, Kiriya J, Perel P, Edwards P, Shakur H & Roberts I. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med 2012; 12: 3.